Argus Downgrades Perrigo Co. (PRGO) to Hold

Announcement Regarding Possible Offer

DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE) notes the announcement made by Mylan NV ("Mylan") (NASDAQ: MYL).  Perrigo confirms that it has received an unsolicited, indicative proposal from Mylan regarding a possible offer for the Company (the "Proposal").

The Board of Perrigo will meet to discuss the Proposal and a further announcement will be made when appropriate.

There can be no certainty that any offer will be made.

About... More

Mylan Proposes To Acquire Perrigo For $205 Per Share

POTTERS BAR, England, April 8, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Mylan has made a proposal to acquire Perrigo Company plc (NYSE: PRGO) in a cash-and-stock transaction that would create a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile. The combination of these highly complementary businesses would produce a company with critical mass in specialty brands, generics, over-the-counter (OTC) and nutritional products; a powerful commercial platform with reach across... More

Perrigo Announces FDA Approval and Upcoming Launch of the AB Therapeutic Equivalent to Exalgo®

DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application for hydromorphone HCI extended-release tablets 8 mg, 12 mg and 16 mg. The FDA concluded that Perrigo's products are therapeutically equivalent to Mallinckrodt Inc.'s Exalgo® 8 mg, 12 mg and 16 mg and can be substituted with the full expectation that it will produce the same clinical effect and safety profile when used under the conditions specified in the labeling. Shipments to our pharmacy customers will commence... More